Granted Patent
B2
US 12,285,393 · App. 17/942,657 · Granted Apr 29, 2025
Roles of modulators of intersectin-Cdc42 signaling in Alzheimer's disease
Inventors:
Qun Lu (Greenville, NC); Yan-Hua Chen (Greenville, NC); Yi Zhu (Greenville, NC); Byron Aguilar (Greenville, NC)
Assignee:
Qun Lu
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of treating Alzheimer's disease and other neurodegenerative and/or neurocognitive and/or neurodevelopmental diseases are described. The methods comprise the administration of compounds that modulate an activity of cell division control protein 42 (Cdc42), such as the interaction between Cdc42 and intersectin (ITSN). Exemplary modulator compounds include thioureas, disulfonamides of fused aromatic systems (e.g., benzofuran), and acyl hydrazones, among others. Some of the modulator compounds act as activators of Cdc42, while others act as inhibitors. In some cases, the modulator compound has dual functionality and the ability of the modulator compound to act as an inhibitor or activator depends on whether or not Cdc42 is already activated in a particular disease stage or biological environment by an upstream activating signal of Cdc42.
Claims (2)
1. A method of treating Alzheimer's disease in a subject in need of treatment thereof, wherein the method comprises administering to the subject a compound having the structure:
or a pharmaceutically acceptable salt thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 12, 2022
From: LU, QUN; AGUILAR, BYRON; ZHU, YI; CHEN, YAN-HUA
To: EAST CAROLINA UNIVERSITY
Reel/Frame 061063/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 12, 2022
From: EAST CAROLINA UNIVERSITY
To: LU, QUN
Reel/Frame 061063/0651 →
Continuity (3)
Provisional Application
62562816
· Sep 25, 2017
References Cited (226)
US 5628984A
· Boucher, Jr.
· 1997
[cited by applicant]
US 8658655B2
· Peterson et al.
· 2014
[cited by applicant]
US 9433663B2
· Zheng
· 2016
[cited by applicant]
US 9642835B2
· Wandinger-Ness et al.
· 2017
[cited by applicant]
US 9725417B2
· Chen et al.
· 2017
[cited by applicant]
US 9873661B2
· Cardozo et al.
· 2018
[cited by applicant]
US 20140194451A1
· Lu et al.
· 2014
[cited by applicant]
US 20140256767A1
· Hu et al.
· 2014
[cited by applicant]
US 20190040393A1
· Postrel
· 2019
[cited by applicant]
AU 2685299A
· 1999
[cited by applicant]
AU 2002302363B2
· 2008
[cited by applicant]
AU 2009242126B2
· 2014
[cited by applicant]
AU 2009242113B2
· 2014
[cited by applicant]
AU 2014217962A1
· 2015
[cited by applicant]
CN 102796050B
· 2014
[cited by applicant]
CN 109925510A
· 2019
[cited by applicant]
EA 201500836A1
· 2016
[cited by applicant]
EP 1504760A1
· 2005
[cited by applicant]
EP 1370543B1
· 2006
[cited by applicant]
EP 2195304B1
· 2014
[cited by applicant]
EP 2716292B1
· 2017
[cited by applicant]
EP 2496226B1
· 2020
[cited by applicant]
JP 2002504502A
· 2002
[cited by applicant]
JP 2004503462A
· 2004
[cited by applicant]
JP 2013540720A
· 2013
[cited by applicant]
JP 2014205697A
· 2014
[cited by applicant]
JP 6001650B2
· 2016
[cited by applicant]
JP 6062995B2
· 2017
[cited by applicant]
KR 20010041605A
· 2001
[cited by applicant]
KR 20130065899A
· 2013
[cited by applicant]
KR 101399056B1
· 2014
[cited by applicant]
NZ 589304A
· 2012
[cited by applicant]
NZ 589307A
· 2012
[cited by applicant]
WO WO9955667A1
· 1999
[cited by applicant]
WO WO2011022393A2
· 2011
[cited by applicant]
WO WO2011104411A2
· 2011
[cited by applicant]
WO WO2012027548A1
· 2012
[cited by applicant]
WO WO2014124978A2
· 2014
[cited by applicant]
WO WO2019140300A1
· 2019
[cited by applicant]
WO WO2018213150A8
· 2020
[cited by applicant]
Friesland et al PNAS, 2013, 110(4), 1261-1266 (Year: 2013).
[cited by examiner]
Abramov et al., “β-Amyloid Peptides Induce Mitochondrial Dysfunction and Oxidative Stress in Astrocytes and Death of Neurons through Activation of NADPH Oxidase,” J. Neurosci., vol. 24, No. 2, pp. 565-575 (2004).
[cited by applicant]
Aguilar et al., “Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth,” Cancer Biology & Therapy, pp. 1-21 (2018).
[cited by applicant]
Aguilar et al., “Rho GTPases as therapeutic targets in Alzheimer's disease,” Alzheimer's Research & Therapy, vol. 9, No. 97, pp. 1-10 (2017).
[cited by applicant]
Aloizou et al. “Pesticides, Cognitive functions and dementia: A review”, Toxicology Letters, vol. 326, pp. 31-51 (2020).
[cited by applicant]
Alzheimer's and Dementia, vol. 9, No. 4, Supp. 1, pp. 893-P894. Abstract No. P4-432 (Year: 2013).
[cited by applicant]
Amano et al., “Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase,” J. Neurochem., vol. 87, pp. 780-790 (2003).
[cited by applicant]
Ba et al., “Rho GTPase signaling at the synapse: implications for intellectual disability,” Exp. Cell Res. vol. 319 pp. 2368-2374 (2013).
[cited by applicant]
Belfiore et al., “Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice,” Aging Cell, pp. 1-13 (2019).
[cited by applicant]
Berezovska et al., “Notch1 and Amyloid Precursor Protein Are Competitive Substrates for Presenilin1-dependent γ-Secretase Cleavage,” J. Biol. Chem., vol. 276, No. 32, pp. 30018-30023 (2001).
[cited by applicant]
Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci., vol. 66, pp. 1-19 (1977).
[cited by applicant]
Blalock et al., “Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses,” Proc. Natl. Acad. Sci. U.S.A., vol. 101, No. 7, pp. 2173-2178 (2004).
[cited by applicant]
Bolognin et al., “The Potential Role of Rho GTPases in Alzheimer's Disease Pathogenesis,” Mol. Neurobiol. 2014;50:406-22.
[cited by applicant]
Boo et al., “Rac1 changes the substrate specificity of gamma-secretase between amyloid precursor protein and Notch1,” Biochem. Biophys. Res. Commun., vol. 372 pp. 913-917 (2008).
[cited by applicant]
Boquet, “The cytotoxic necrotizing factor 1 (CNF1) from
[cited by applicant]
Borin et al., “Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer's disease,” Acta Neuropathologica Communications, vol. 6, No. 61 (2018).
[cited by applicant]
Brewer & Torricelli, “Isolation and culture of adult neurons and neurospheres,” Nat. Protoc., vol. 2 No. 6, pp. 1490-1498 (2007).
[cited by applicant]
Cannon, J.G., “Analog Design,” Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience, pp. 783-802 (Year: 1995).
[cited by applicant]
Caprioli et al., “Partial Purification and Characterization of an
[cited by applicant]
Cataldo et al., “Endocytic Pathway Abnormalities Precede Amyloid β Deposition in Sporadic Alzheimer's Disease and Down Syndrome: Differential Effects of APOE Genotype and Presenilin Mutations,” Am. J. Pathol. 2000; 157:…
[cited by applicant]
Cerri et al., “Activation of Rho GTPases Triggers Structural Remodeling and Functional Plasticity in the Adult Rat Visual Cortex,” J. Neurosci. 2011;31:15163-72.
[cited by applicant]
Chou et al., “Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor,” Journal of Virology, vol. 90, No. 9, pp. 4494-4510 (2016).
[cited by applicant]
Cosman et al., “Memantine in the treatment of mild-to-moderate Alzheimer's disease” Expert Opin Pharmacother. Vo. 8 pp. 203-214 (2007).
[cited by applicant]
Cui et al., “Elevated IQGAP1 and CDC42 levels correlate with tumor malignancy of human glioma,” Oncology Reports, vol. 37 pp. 768-776 (2017).
[cited by applicant]
Cummings, J., et al., “The “rights” of precision drug development for Alzheimer's disease,” Alzheimer's Research & Therapy, vol. 11, No. 76, pp. 1-14 (2019).
[cited by applicant]
Datta et al., “Altered Expression of CDC42 Signaling Pathway Components in Cortical Layer 3 Pyramidal Cells in Schizophrenia,” Author manuscript, pp. 1-22, published in final edited form in Biol. Psychiatry, vol. 78, No…
[cited by applicant]
Daubon et al., “Invadopodia and rolling-type motility are specific features of highly invasive p190bcr-abl,” European Journal of Cell Biology, vol. 91, pp. 978-987 (2012).
[cited by applicant]
Davis et al., “Mapping Cofilin-Actin Rods in Stressed Hippocampal Slices and the Role of cdc42 in Amyloid-β-Induced Rods”, Journal of Alzheimer's Disease, 18(1) pp. 35-50 (2009).
[cited by applicant]
Deacon et al., “Age-dependent and -independent behavioral deficits in Tg2576 mice,” Behavioural Brain Research, vol. 189 pp. 126-138 (2008).
[cited by applicant]
Deacon et al., “Hippocampal lesions, species-typical behaviours and anxiety in mice,” Behavioural Brain Research, vol. 156, pp. 241-249 (2005).
[cited by applicant]
Deacon, “Assessing Burrowing, Nest Construction, and Hoarding in Mice,” Journal of Visualized Experiments, vol. 59, e2607, pp. 1-10 (2012).
[cited by applicant]
Deacon, “Assessing nest building in mice,” Nature Protocols, vol. 1, No. 3 pp. 1117-1119 (2006).
[cited by applicant]
Deacon,R.M.J., et al., “Aged Tg2576 mice are impaired on social memory and open field habituation tests,” Behavioural Brain Research, vol. 197 pp. 466-468 (2009).
[cited by applicant]
DeGeer & Lamarche-Vane, “Rho GTPases in neurodegeneration diseases,” Exp. Cell Res., vol. 319, pp. 2384-2394 (2013).
[cited by applicant]
Del Pino, “Primary hippocampal neuronal cell death induction after acute and repeated paraquat exposures mediated by AChE variants alteration and cholinergic and glutamatergic transmission disruption,” Toxicology, vol. …
[cited by applicant]
Diana et al., “Enhancement of learning and memory after activation of cerebral Rho GTPases,” Proc. Natl. Acad. Sci. U.S.A. 2007;104:636-41.
[cited by applicant]
Dorostkar et al., “Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities,” Acta Neuropathol., vol. 130, pp. 1-19 (2015).
[cited by applicant]
Dunckley et al., “Gene expression correlates of neurofibrillary tangles in Alzheimer's disease,” Neurobiol. Aging. 2006;27:1359-71.
[cited by applicant]
Désiré et al., “RAC1 Inhibition Targets Amyloid Precursor Protein Processing by γ-Secretase and Decreases Aβ production in Vitro and in Vivo,” J. Biol. Chem. 2005;280:37516-25.
[cited by applicant]
Eriksen et al., “NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ 42 in vivo,” J. Clin. Invest. 2003;112:440-9.
[cited by applicant]
Etienne-Manneville & Hall, “Rho GTPases in cell biology,” Nature., vol. 420, pp. 629-635 (2002).
[cited by applicant]
Feng et al., “Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential,” J. Med. Chem., vol. 59 pp. 2269-2300 (2016).
[cited by applicant]
Filippis et al., “Modulation of Rho GTPases rescues brain mitochondrial dysfunction, cognitive deficits and aberrant synaptic plasticity in female mice modeling Rett syndrome,” Eur. Neuropsychopharmacol., vol. 25, pp. 8…
[cited by applicant]
Fiorentini et al., “Cytoskeletal changes induced in HEp-2 cells by the cytotoxic necrotizing factor of
[cited by applicant]
Fiorentini et al., “
[cited by applicant]
Flatau et al., “Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine,” Nature. vol. 387, pp. 729-733 (1997).
[cited by applicant]
Fournier et al., “Rho Kinase Inhibition Enhances Axonal Regeneration in the Injured CNS,” J. Neurosci. 2003;23:1416-23.
[cited by applicant]
Friesland et al., “Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility,” Proc. Natl. Acad. Sci. USA, vol. 110, No. 4, pp. 1261-1266 (2013).
[cited by applicant]
Fuhrmann et al., “Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease,” Author manuscript, pp. 1-6, published in final edited form in Nat Neurosci., vol. 13, No. 4, pp. 411-413 (2010).
[cited by applicant]
Gao et al., “Rational design and characterization of a Rac GTPase-specific small molecule inhibitor,” Proc. Natl. Acad. Sci. U.S.A. 2004;101:7618-23.
[cited by applicant]
Geisslinger et al. “Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers,” Br J Clin Pharmacol. 1994;37:392-4.
[cited by applicant]
Green et al., “Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease: A Randomized Controlled Trial,” JAMA. 2009;302:2557-64.
[cited by applicant]
Gunnarson& Bodin, “Occupational Exposure and Neurodegenrative Diseases—A Systematic Literature Review and Meta-Analyses,” International Journal of Environmental Research and Public Health, vol. 16, pp. 1-17 (2019).
[cited by applicant]
Hagberg et al., “An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Bad…
[cited by applicant]
Hamano et al., “Pitavastatin decreases tau levels via the inactivation of Rho/ROCK,” Neurobiology of aging [Internet]. Elsevier; vol. 33, pp. 2306-2320 (2012).
[cited by applicant]
Hardy & Selkoe, “The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics,” Science, vol. 297, pp. 353-356 (2002).
[cited by applicant]
Haskins M, et al., “Early alterations in blood and brain RANTES and MCP-1 expression and the effect of exercise frequency in the 3xTg-AD mouse model of Alzheimer's disease”, Neurosci Lett., vol. 610, pp. 165-170 (2016).
[cited by applicant]
Hernández et al., “Adhesion-Dependent Regulation of p190RhoGAP in the Developing Brain by the Abl-Related Gene Tyrosine Kinase,” Curr. Biol. 2004; 14:691-6.
[cited by applicant]
Herrero-Garcia et al., “Intersectin scaffold proteins and their role in cell signaling and endocytosis,” Biochim. Biophys. Acta. 2017; 1864:23-30.
[cited by applicant]
Herskowitz et al., “Pharmacologic Inhibition of ROCK2 Suppresses Amyloid-β Production in an Alzheimer's Disease Mouse Model,” J. Neurosci. 2013;33:19086-98.
[cited by applicant]
Higa et al., “Vibrio parahaemolyticus Effector Proteins Suppress Inflammasome Activation by Interfering with Host Autophagy Signaling,” PLoS Pathog vol. 9, No. 1 (2013).
[cited by applicant]
Hong et al., “Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models,” Author Manuscript, pp. 1-14, published in final edited form in Science, vol. 352, No. 6286, pp. 712-716 (2016).
[cited by applicant]
Hong L et al., “Characterization of a Cdc42 Protein Inhibitor and Its Use as a Molecular Probe,” J. Biol. Chem. 2013;288:8531-43.
[cited by applicant]
Hori et al., “Cytoskeletal Regulation by AUTS2 in Neuronal Migration and Neuritogenesis,” Cell Rep., vol. 9, No. 6, pp. 2166-2179 (2014).
[cited by applicant]
Hsiao et al., “Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice,” Science. 1996;274:99-102.
[cited by applicant]
Hsiao K. “Transgenic mice expressing Alzheimer amyloid precursor proteins,” Exp. Gerontol. vol. 33, pp. 883-889 (1998).
[cited by applicant]
Huang et al., “Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease,” J. Mol. Neurosci., vol. 23:189-204 (2004).
[cited by applicant]
Huebner et al., “Maternal Iron Deficiency Worsens the Associative Learning Deficits and Hippocampal and Cerebellar Losses in a Rat Model of Fetal Alcohol Spectrum Disorders,” Author manuscript, pp. 1-21, Published in fi…
[cited by applicant]
Huesa G, Baltrons MAA, Gómez-Ramos P, Morán A, García A, Hidalgo J, et al. Altered distribution of RhoA in Alzheimer's disease and AbetaPP overexpressing mice. J. Alzheimers Dis. 2010;19:37-56.
[cited by applicant]
Hunter et al., “Emerging Roles for Intersectin (ITSN) in Regulating Signaling and Disease Pathways,” Int J Mol Sci. 2013;14:7829-52.
[cited by applicant]
Hunter et al., “Intersectin 1 contributes to phenotypes in vivo: implications for Down Syndrome,” Author manuscript, pp. 1-10, Published in final edited form in Neuroreport, vol. 22, No. 15, pp. 767-772 (2011).
[cited by applicant]
Ide et al., “Altered cortical CDC42 signaling pathways in schizophrenia: Implications for dendritic spine deficits,” Author manuscript, pp. 1-18, Published in final edited form in Biol. Psychiatry, vol. 68, No. 1, pp. 2…
[cited by applicant]
Ivkovich et al., Effects of Early Hippocampal Lesions on Trace, Delay, and Long-Delay Eyeblink Conditioning in Developing Rats Neurobiol. Learn. Mem., vol. 76, pp. 426-446 (2001).
[cited by applicant]
Jans et al., “Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease,” Cardiovascular & Haematological Disorders—Drugs Targets, vol. 6, pp. 21-34 (2006).
[cited by applicant]
Jones S. B., et al., “Abl tyrosine kinase promotes dendrogenesis by inducing actin cytoskeletal rearrangements in cooperation with Rho family small GTPases in hippocampal neurons”, J Neurosci. 24 (39), pp. 8510-8521 (20…
[cited by applicant]
Kato et al., “Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients,” Neurosci Lett. vol. 591, pp. 19-24 (2015).
[cited by applicant]
Kim et al., “Compromised MAPK signaling in human diseases: an update,” Arch. Toxicol. 2015;89:867-82.
[cited by applicant]
Koppel et al., “Optimal treatment of Alzheimer's disease psychosis: challenges and solutions,” Neuropsychiatric Disease and Treatment, vol. 10, pp. 2253-2262 (2014).
[cited by applicant]
Kumari et al., “Exosomal protein interactors as emerging therapeutic targets in urothelial bladder cancer,” J. Egypt Natl. Canc. Inst., vol. 27, No. 2, pp. 51-58 (2015).
[cited by applicant]
Kuns et al. “Memantine” StatPear Publishing, accessed Jan. 2020, pp. 1-9.
[cited by applicant]
Lee et al., “Selective axonal translation of prenylated Cdc42 mRNA isoform supports axon growth,” The Journal of Neuroscience, pp. 1-37 (2018).
[cited by applicant]
Lefort, “Reversing Synapse Loss in Alzheimer's Disease: Rho-Guanosine Triphosphatases and Insights from Other Brain Disorders,” Neurotherapeutics. 2015;12:19-28.
[cited by applicant]
Leuchtenberger et al., “Inhibitors of Rho-kinase modulate amyloid-β (AB) secretion but lack selectivity for Aβ42,” J. Neurochem. 2006;96:355-65.
[cited by applicant]
Liao et al., “Rho Kinase (ROCK) Inhibitors,” J. Cardiovasc. Pharmacol. 2007;50:17-24.
[cited by applicant]
Lim et al., “Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice,” Neurobiol. Of Aging., vol. 22, pp. 983-991 (2001).
[cited by applicant]
Loizzo et al., “CNF1 Increases Brain Energy Level, Counteracts Neuroinflammatory Markers and Rescues Cognitive Deficits in a Murine Model of Alzheimer's Disease,” PLoS ONE. 2013;8:e65898.
[cited by applicant]
Lu et al., “Signaling Through Rho GTPase Pathway as Viable Drug Target,” Curr Med Chem., vol. 16, No. 11, pp. 1355-1365 (2009).
[cited by applicant]
Lu Q, et al., “Alzheimer disease-linked presenilin mutation (PS1M146L) induces filamin expression and γ-secretase independent redistribution”, Journal of Alzheimer's Disease, 22 (1) pp. 235-245 (2010).
[cited by applicant]
Lu Q, Wood John, “Functional studies of Alzheimer's disease tau protein,” J Neurosci., vol. 13, pp. 508-515 (1993).
[cited by applicant]
Luca et al., “Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein,” Eur. J. Pharmacol. vol. 405, pp. 277-283 (2000).
[cited by applicant]
Luo, L., “Rho GTPases in Neuronal Morphogenesis,” Nat. Rev. Neurosci., vol. 1, pp. 173-180, 2000.
[cited by applicant]
Lövheim et al., “Herpes simplex infection and the risk of Alzheimer's disease: A nested case-control study,” Alzhiemer's & Dementia, vol. 11, pp. 587-592 (2015).
[cited by applicant]
Manterola et al., “1-42 β-Amyloid peptide requires PDK1/nPKC/Rac 1 pathway to induce neuronal death,” Transl Psychiatry. 2013;3:e219.
[cited by applicant]
Marco et al., “ARHGEF9 disruption in a female patient is associated with X linked mental retardation and sensory hyperarousal,” J. Med. Genet., vol. 45, pp. 100-105 (2008).
[cited by applicant]
Masliah, “Mechanisms of synaptic dysfunction in Alzheimer's disease,” Histol. Histopathol., vol. 10, 509-19 (1995).
[cited by applicant]
Matsui et al., “Involvement of the γ-secretase-mediated EphA4 signaling pathway in synaptic pathogenesis of Alzheimer's disease,” Brain Pathol., vol. 22, pp. 776-787 (2012).
[cited by applicant]
Matus, “Actin-based plasticity in dendritic spines,” Science., vol. 290, pp. 754-758 (2000).
[cited by applicant]
Mehta, D., et al., “Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015,” Expert Opinion On Investigational Drugs, vol. 26, No. 6, pp. 735-739 (Year: 2017).
[cited by applicant]
Mendoza-Naranjo et al., “Aβ1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases,” J. Cell. Sci. 2007; 120:279-88.
[cited by applicant]
Mesulam, “Neuroplasticity Failure in Alzheimer's Disease: Bridging the Gap between Plaques and Tangles,” Neuron. 1999;24:521-9.
[cited by applicant]
Moresco et al., “Abl Family Nonreceptor Tyrosine Kinases Modulate Short-Term Synaptic Plasticity,” J. Neurophysiol. 2003;89:1678-87.
[cited by applicant]
Morris, “Developments of a water-maze procedure for studying spatial learning in the rat,” Journal of Neuroscience Methods, vol. 11, pp. 47-60 (1984).
[cited by applicant]
Moutin et al., “Palmitoylation of cdc42 Promotes Spine Stabilization and Rescues Spine Density Deficit in a Mouse Model of 22q11.2 Deletion Syndrome,” Cereb. Cortex, vol. 27, No. 7, pp. 3618-3629 (2017).
[cited by applicant]
Munoz & Ammit, “Targeting p38 MAPK pathway for the treatment of Alzheimer's disease,” Neuropharmacology., vol. 58, pp. 561-568 (2010).
[cited by applicant]
Murray et al., “Psychosis in Alzheimer's Disease,” Author Manuscript, pp. 1-24, published in final edited form in Biol Psychiatry, vol. 75, No. 7, pp. 542-552 (2014).
[cited by applicant]
Musilli et al., “Behavioral effects of Rho GTPase modulation in a model of Alzheimer's disease,” Behav. Brain Res. vol. 237, pp. 223-229 (2013).
[cited by applicant]
Nadif Kasri et al., “Rho-linked genes and neurological disorders,” Pflugers Arch. 2008;455:787-97.
[cited by applicant]
Newey et al., “Rho GTPases, dendritic structure, and mental retardation,” J. Neurobiol., vol. 64, pp. 58-74 (2005).
[cited by applicant]
Nicoll, R., “A Brief History of Long-Term Potentiation,” Neuron, vol. 93, pp. 281-290 (2017).
[cited by applicant]
Oakley et al., “Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation,” J. Neurosci. 20…
[cited by applicant]
Oddo et al., “Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles: Intracellular Aβ and Synaptic Dysfunction,” Neuron, vol. 39, pp. 409-421 (2003).
[cited by applicant]
Office Action (Final Rejection) corresponding to U.S. Appl. No. 16/141,849, filed Apr. 16, 2021, pp. 10.
[cited by applicant]
Office Action (Non-Final Rejection) corresponding to U.S. Appl. No. 16/141,849, filed Aug. 10, 2020, pp. 8.
[cited by applicant]
Office Action (Non-Final Rejection) corresponding to U.S. Appl. No. 16/141,849, filed Jul. 3, 2019, pp. 11.
[cited by applicant]
Office Action (Non-Final Rejection) corresponding to U.S. Appl. No. 16/141,849, filed Mar. 3, 2020, pp. 16.
[cited by applicant]
Office Action (Notice of Allowance) corresponding to U.S. Appl. No. 16/141,849, filed Jan. 27, 2022, pp. 9.
[cited by applicant]
Office Action (Notice of Allowance) corresponding to U.S. Appl. No. 16/141,849, filed May 4, 2022, pp. 9.
[cited by applicant]
Office Action (Notice of Allowance) corresponding to U.S. Appl. No. 16/141,849, filed Sep. 22, 2021, pp. 11.
[cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 16/141,849, filed Mar. 8, 2019, pp. 6.
[cited by applicant]
Oprea et al., “Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases,” PLoS ONE. 2015;10:e0142182.
[cited by applicant]
Oswald et al., “Detection of
[cited by applicant]
Otth et al., “Modulation of the JNK and p38 pathways by cdk5 protein kinase in a transgenic mouse model of Alzheimer's disease,” Neuroreport., vol. 14, pp. 2403-2409 (2003).
[cited by applicant]
O'Kane et al., “Activation of Rho GTPases by synaptic transmission in the hippocampus,” J. Neurochem., vol. 87, pp. 1309-1312 (2003).
[cited by applicant]
Palop et al., “A network dysfunction perspective on neurodegenerative diseases,” Nature., vol. 443, pp. 768-773 (2006).
[cited by applicant]
Park et al., “Annexin A1 restores Aβ1-42-induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway,” Aging Cell., vol. 16, No. 1, pp. 149-161 (2017).
[cited by applicant]
Peacock et al., “The Abl-related Gene Tyrosine Kinase Acts through p190RhoGAP to Inhibit Actomyosin Contractility and Regulate Focal Adhesion Dynamics upon Adhesion to Fibronectin,” Mol. Biol. Cell. 2007;18:3860-72.
[cited by applicant]
Penzes et al., “Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease,” Brain Res Rev. 2011;67:184-92.
[cited by applicant]
Perrett et al., “Cerebellar Cortex Lesions Disrupt Learning-dependent Timing of Conditioned Eyelid Responses,” J. Neuroscience, vol. 13, No. 4, pp. 1708-1718 (1993).
[cited by applicant]
Petratos et al., “The β-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism,” Brain. 2008; 131:90-108.
[cited by applicant]
Pozueta et al., “Caspase-2 is required for dendritic spine and behavioral alterations in J20 APP transgenic mice,” Nat Commun. 2013;4:1939.
[cited by applicant]
Raad et al., “Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma,” Electrophoresis., vol. 33, pp. 3659-3668 (2012).
[cited by applicant]
Ramakers et al., “Dysregulation of Rho GTPases in the αPix/Arhgef6 mouse model of X-linked intellectual disability is paralleled by impaired structural and synaptic plasticity and cognitive deficits,” Hum. Mol. Genet. 2…
[cited by applicant]
Restivo et al., “The Formation of Recent and Remote Memory is Associated with Time-Dependent Formation of Dendritic Spines in the Hippocampus and Anterior Cingulate Cortex,” J. Neurosci. 2009;29:8206-14.
[cited by applicant]
Rex et al., “Different Rho GTPase-dependent signaling pathways initiate sequential steps in the consolidation of long-term potentiation,” J. Cell Biol. 2009;186:85-97.
[cited by applicant]
Rogers et al., “Clinical trial of indomethacin in Alzheimer's disease,” Neurology. vol. 43, pp. 1609-1611 (1993).
[cited by applicant]
Rufer et al., “Adequacy of Maternal Iron Status Protects against Behavioral, Neuroanatomical, and Growth Deficits in Fetal Alcohol Spectrum Disorders,” PLoS One, vol. 7, No. 10, e47499, pp. 1-12 (2012).
[cited by applicant]
Sagi et al., “The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 production,” …
[cited by applicant]
Saitoh et al., “ROCK inhibition produces anxiety-related behaviors in mice,” Psychopharmacology (Berl.). vol. 188, pp. 1-11 (2006).
[cited by applicant]
Salloum et al., “Rho A and Rac1: Antagonists moving forward,” Tissue and Cell, vol. 65, pp. 1-5 (2020).
[cited by applicant]
Saraceno et al., “Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration,” Journal of Alzheimer's Disease, vol. 61, 1477-1483 (2018).
[cited by applicant]
Scheff et al., “Is synaptic loss a unique hallmark of Alzheimer's disease?” Biochem. Pharmacol. 2014;88:517-28.
[cited by applicant]
Schmidt et al., “Gln 63 of Rho is deamidated by
[cited by applicant]
Selkoe, “Alzheimer's disease is a synaptic failure,” Science., vol. 298, pp. 789-791 (2002).
[cited by applicant]
Sfakianos et al., “Inhibition of Rho via Arg and p190RhoGAP in the Postnatal Mouse Hippocampus Regulates Dendritic Spine Maturation, Synapse and Dendrite Stability, and Behavior,” J. Neurosci. 2007;27:10982-92.
[cited by applicant]
Shen et al., “The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism,” PNAS, vol. 104, No. 2, pp. 403-409 (2007).
[cited by applicant]
Sims et al., “Rare coding variants in PLCG2, ABI3 and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease,” Nat. Genet., vol. 49, No. 9, pp. 1373-1384 (2017).
[cited by applicant]
Skelton, “Bilateral cerebellar lesions disrupt conditioned eyelid responses in unrestrained rats,” Behav. Neuroscience, vol. 102, No. 4, pp. 586-590 (1988).
[cited by applicant]
Sonkar et al., “Amyloid β peptide stimulates platelet activation through RhoA-dependent modulation of actomyosin organization,” FASEB J., vol. 28, pp. 1819-1829 (2014).
[cited by applicant]
Spillane et al., “Involvement of Rho-family GTPases in axon branching,” Small GTPases. 2014;5:e27974.
[cited by applicant]
Stankiewicz et al., “Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration,” Front Cell Neurosci. 2014;8:314.
[cited by applicant]
Sterniczuk et al., Characterization of the 3xTg-AD mouse model of Alzheimer's disease: Part 2. Behavioral and cognitive changes, Brain Research, vol. 1348, pp. 149-155 (2010).
[cited by applicant]
Strooper et al., “A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain,” Nature. 1999;398:518-22.
[cited by applicant]
Tahirovic et al., “Rac1 Regulates Neuronal Polarization through the WAVE Complex,” J. Neurosci. 2010;30:6930-43.
[cited by applicant]
Takahashi et al., “Sulindac Sulfide Is a Noncompetitive γ-secretase Inhibitor That Preferentially Reduces Aβ42 Generation,” J. Biol. Chem. 2003;278:18664-70.
[cited by applicant]
Tanzi et al., “Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective,” Cell. 2005;120:545-55.
[cited by applicant]
Tashiro & Yuste, “Role of Rho GTPases in the morphogenesis and motility of dendritic spines,” Meth. Enzymol. vol. 439, pp. 285-302 (2008).
[cited by applicant]
Tashiro et al., “Regulation of Dendritic Spine Morphology by the Rho Family of Small GTPases: Antagonistic Roles of Rac and Rho,” Cerebral Cortex, vol. 10, pp. 927-938 (2000).
[cited by applicant]
Terry et al., “Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment,” Ann. Neurol., vol. 30, pp. 572-580 (1991).
[cited by applicant]
Terry, “A Long Line of Alzheimer's Failures: Roche Drops Two Drug Trials,” BioSpace, pp. 1-3, https://www.biospace.com/article/a-long-line-of-failures-roche-drops-alzheimer-s-drug-trials/ (retrieved from the internet Fe…
[cited by applicant]
Thomas & Tran, “Choline Supplementation Mitigates Trace, but not Delay, Eyeblink Conditioning Deficits in Rats Exposed to Alcohol During Development,” Hippocampus, vol. 22, pp. 619-630 (2012).
[cited by applicant]
Tran et al., Binge-Like Ethanol Exposure During the Early Postnatal Period Impairs Eyeblink Conditioning at Short and Long CS-US Intervals in Rats, Dev. Psychibiol., vol. 49, pp. 589-605 (2007).
[cited by applicant]
Tsyba et al., “Intersectin multidomain adaptor proteins: regulation of functional diversity,” Gene., vol. 473, pp. 67-75 (2011).
[cited by applicant]
Uddin et al., “Multi-Target Drug Candidates for Multifactiorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets,” Molecular Neurobiology, vol. 58, pp. 281-303 (2021).
[cited by applicant]
Van Aelst & Cline, “Rho GTPases and activity-dependent dendrite development,” Curr. Opin. Neurobiol. vol. 14, pp. 297-304 (2004).
[cited by applicant]
Wang et al., “Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene,” J. Neurosci. Res., vol. 87, pp. 2105-2114 (2009).
[cited by applicant]
Webster et al., “Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models,” Frontiers in Genetics, vol. 5 pp. 1-23 (2014).
[cited by applicant]
Weggen et al., “A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity,” Nature., vol. 414, pp. 212-216 (2001).
[cited by applicant]
Weggen et al., “Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain,” J. Biol.…
[cited by applicant]
Williamson et al., “Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in Response to Amyloid-β Peptide Exposure: Involvement of Src Family Protein Kinases,” J. Neurosci. 2002;22…
[cited by applicant]
Wilmot et al., “Translational gene mapping of cognitive decline,” Neurobiol. Aging. 2008;29:524-41.
[cited by applicant]
Wong et al., “Intersectin (ITSN) Family of Scaffolds Function as Molecular Hubs in Protein Interaction Networks,” PLoS One, vol. 7, Iss. 4, e36023, pp. 1-9 (2012).
[cited by applicant]
Wu et al., “Ack1 is a dopamine transporter endocytic brake thatrescues a trafficking-dysregulated ADHDcoding variant,” Proc. Natl. Acad. Sci., USA, vol. 112, No. 50, pp. 15480-15485 (2015).
[cited by applicant]
Wu et al., “Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer's disease,” Protein & Cell, vol. 10, No. 10, pp. 745-759 (2019).
[cited by applicant]
Yankner et al., “Amyloid β-Protein Toxicity and the Pathogenesis of Alzheimer Disease,” Journal of Biological Chemistry, vol. 284, No. 8, pp. 4755-4759 (2009).
[cited by applicant]
Yankner et al., “Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides,” Science, vol. 250, Issue 4978, pp. 279-282 (1990).
[cited by applicant]
Yarza et al., “c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease,” Front Pharmacol. 2015;6:321.
[cited by applicant]
Zhao et al., “Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease,” Nat. Neurosci., vol. 9, pp. 234-242 (2006).
[cited by applicant]
Zhao et al., “Targeting protein-protein interactions in Rho GTPase regulation using small molecules,” Science Supplement, pp. 71-72 (2016).
[cited by applicant]
Zhou et al., “Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho,” Science., vol. 302, pp. 1215-1217 (2003).
[cited by applicant]
Zhu et al., “Activation of oncogenic pathways in degenerating neurons in Alzheimer disease,” Int. J. Dev. Neurosci., vol. 18, pp. 433-437 (2000).
[cited by applicant]
Zhu et al., “Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the “two hit” hypothesis,” Mech. Ageing Dev., vol. 123:39-46 (2001).
[cited by applicant]
Zins et al., “A Rac1/Cdc42 GTPase-Specific Small Molecule Inhibitor Suppresses Growth of Primary Human Prostate Cancer Xenografts and Prolongs Survival in Mice,” PLoS ONE. 2013;8:e74924.
[cited by applicant]